A Study to Evaluate MEDI5752 and Axitinib in Subjects with Advanced Renal Cell Carcinoma

Trial Identifier: D7980C00003
Sponsor: MedImmune, LLC
Start Date: August 2020
Primary Completion Date: September 2025
Study Completion Date: September 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Frankston, AU, 3199
AU Waratah, AU, 2298
ES Barcelona, ES, 08025
ES Barcelona, ES, 08908
ES Barcelona, ES, 08003
ES Barcelona, ES, 08035
ES Córdoba, ES, 14004
ES Madrid, ES, 28041
ES Madrid, ES, 28040
ES Sabadell, ES, 08208
ES Sevilla, ES, 41013
ES Valencia, ES, 46009
FR Villejuif Cedex, FR, 94805
US, DC Washington, DC, US, 20007
US, FL Fort Myers, FL, US, 33908
US, MO Saint Louis, MO, US, 63156
US, NY New York, NY, US, 10065
US, OH Cleveland, OH, US, 44195
US, PA Hershey, PA, US, 17033
US, TN Nashville, TN, US, 37232